WuXi生物logics和HanchorBio合作伙伴利用WuXi的生物实验服务开发和制造用于癌症和自免疫治疗的下一代聚变蛋白。 WuXi Biologics and HanchorBio partner to develop and manufacture next-gen fusion proteins for cancer and autoimmune treatments using WuXi’s biologics services.

WuXi生物logics和HanchorBio建立了战略伙伴关系,利用WuXi的端到端生物学服务开发和制造HanchorBio的下一代聚变蛋白,包括细胞线开发、工艺优化和GMP制造。 WuXi Biologics and HanchorBio have formed a strategic partnership to develop and manufacture HanchorBio’s next-generation fusion proteins using WuXi’s end-to-end biologics services, including cell line development, process optimization, and GMP manufacturing. 合作支持HanchorBio的Fc-Developmenter Biologics平台,目的是通过针对天生免疫和适应性免疫来治疗癌症和自发免疫疾病。 The collaboration supports HanchorBio’s Fc-Based Designer Biologics platform, aimed at treating cancer and autoimmune diseases by targeting both innate and adaptive immunity. WuXi生物logics将利用其在复杂的生物学和专有平台方面的专门知识,加速临床发展,并促成可扩展的全球生产。 WuXi Biologics will leverage its expertise in complex biologics and proprietary platforms to accelerate clinical development and enable scalable, global production. 截至2025年底,WuXi管理了945个项目,其中60%的重点放在先进的生物学上。 As of late 2025, WuXi managed 945 projects, with 60% focused on advanced biologics. 该伙伴关系强调速度、制造业的稳健性和全球合规性,以便为患者带来创新疗法。 The partnership emphasizes speed, manufacturing robustness, and global compliance to bring innovative therapies to patients.